On December 1, 2025, the World Health Organization (WHO) released its first official guidance concerning GLP-1 drugs, aiming to address the pressing issue of obesity globally. The announcement follows a recognition of obesity as a complex, chronic disease affecting over one billion people worldwide, with a predicted rise in its prevalence. The new guidelines are intended to provide a systematic approach for utilizing GLP-1 therapies in long-term obesity treatment for adults, while cautioning against their use in pregnant women due to health uncertainties. The WHO emphasized that the rising obesity rates are not only a health concern but also a financial strain, projecting the cost of obesity management will reach $3 trillion annually by 2030. This health crisis is compounded by the fact that obesity contributes to various other significant health problems, including cardiovascular diseases, type 2 diabetes, and certain cancers. Despite the potential benefits of GLP-1 medications, the WHO noted that only a small fraction—less than 10%—of individuals who would benefit from these therapies are expected to have access to them by 2030. The guidelines outline two conditional recommendations. Firstly, GLP-1 therapies may be employed for adults as long-term treatment for obesity, acknowledging the efficacy observed in improving various related health outcomes. However, this recommendation is conditional due to the limited data available regarding long-term efficacy and safety, as well as factors such as cost and preparedness of health systems. The second recommendation calls for urgent action to ensure fair access to GLP-1 therapies, emphasizing that without strategic measures, existing health inequities could worsen. Dr. Tedros Adhanom Ghebreyesus, the director-general of the WHO, stressed that tackling obesity demands comprehensive and lifelong care. The organization underlines the importance of collective efforts to enhance access to GLP-1 therapies through strategies like pooled procurement, tiered pricing, and voluntary licensing. The WHO calls on countries worldwide to prioritize initiatives that would align with the guidelines and expand availability, thereby addressing both health and economic implications of obesity on a global scale.

The World Health Organization (WHO) has established comprehensive obesity treatment guidelines aimed at addressing the growing obesity epidemic that affects millions worldwide. Recognizing obesity as a complex, multifactorial chronic disease, these guidelines emphasize the need for a holistic approach in treatment that encompasses behavioral, pharmacological, and surgical interventions. The increasing burden of obesity is related to numerous health complications including cardiovascular diseases, diabetes, and certain forms of cancer, thereby necessitating early intervention. WHO emphasizes the importance of personalized treatment plans tailored to individual patient characteristics, including their medical history, preferences, and the presence of comorbidities, in order to maximize effectiveness and ensure sustained weight loss and improvement in quality of life. Healthcare providers are encouraged to use a shared-decision making process that empowers individuals to actively participate in their treatment. A critical element of the WHO obesity treatment guidelines is the incorporation of lifestyle modifications as a cornerstone of therapy. This is aimed at promoting sustainable changes in dietary habits and physical activity. The guidelines advocate for a multi-faceted approach that includes nutritional counseling, behavioral therapy, and support groups, recognizing that individual motivations and barriers to change can vary significantly. Structured programs that facilitate consistent physical activity and healthy eating patterns have been shown to improve outcomes. In addition to lifestyle alterations, the guidelines suggest pharmacotherapy for patients with a body mass index (BMI) of 30 or greater, or those with a BMI of 27 or greater with weight-related comorbidities, as an adjunct to lifestyle modifications. Evidence-based medications can aid in weight management by promoting satiety, reducing appetite, or increasing energy expenditure. Surgical interventions are also outlined within the WHO guidelines as an option for individuals with severe obesity (BMI ≥ 40 or ≥ 35 with obesity-related comorbidities) who have not achieved significant weight loss through other means. Bariatric surgery has been shown to provide substantial and sustained weight loss and is associated with improvements in obesity-related conditions. The decision for surgical treatment must be made collaboratively, ensuring that patients are fully informed about the potential risks and benefits, as well as the need for long-term follow-up post-surgery. Moreover, the WHO emphasizes that specialized care from a multidisciplinary team, including surgeons, dieticians, psychologists, and physical trainers, is vital for achieving optimal results following surgical interventions. The guidelines also highlight the role of public health initiatives in addressing obesity at the population level. Advocacy for policy approaches that promote healthier environments, such as regulations on food marketing, improvements in food labeling, and enhanced access to physical activity facilities, are critical in the efforts to prevent obesity from a young age. Furthermore, educational campaigns aimed at increasing awareness about the risks of obesity and the importance of healthy lifestyle choices are essential. The WHO guidelines recognize that addressing obesity requires collective action from individuals, healthcare providers, and governments to create systematic changes that support healthy living. As the 2025 target approaches, the implementation of these guidelines will be crucial in reversing the obesity trend and improving the health of populations globally.